



Ryah Medtech, Inc.
Investor Presentation

Our Advantage

1. RYAH: Dose Measuring Vaporizer

The world's first dose measuring and data aggregator vaporizer. With a proprietary air flow sensor, RYAH is the only dry-herb device capable of measuring how much vapor a patient inhales for dose management and plant / tobacco control. RYAH puts doctors and patients in control of their medication regimens




2. Big Data Analytics

A unique, herb-based algorithm that uses the latest peer-reviewed research to recommend strains that show the most promise in relieving a patient's symptoms

Result:

A complete digital ecosystem and IoT solution and data-as-a-service for the medical industry.



RYAH


RYAH is the first dose-measuring vaporizer geared to improve and optimize dispensary/LP business model by sharing HIPPA-compliant data on their patients' strain consumption.

RYAH helps partners build a recurring revenue ecosystem with disposable cartridges and make strategic decisions on herb strain planning and patient recommendations.

Data insights based on strain and consumption analytics collected by the RYAH app are provided exclusively to our partners to stand out from competitors as a medical service not available elsewhere. Over 180,000 patients and participants on our database.



WHAT MAKES RYAH UNIQUE



QR CARTRIDGES

Track your strains from seed to consumption and create a closed-loop, recurring revenue ecosystem that will have your customers frequently returning for more cartridges



TEMP & DOSE CONTROL

Patients can enjoy a medical experience not offered elsewhere by fine-tuning their vapor production, selecting the ideal temperature for their sessions, and setting limits on how much they want to inhale



INSIGHTFUL DATA

Automatically capture demographic and consumption data from the RYAH app to see which cartridges are being used, how effective they are for your patients, and which cartridges are enjoyed the most by specific demographics

HOW THE MODEL WORKS:



RYAH provides partner with a filling line




Partner purchases empty cartridges



Partner fills empty cartridges with herb and sets their own price point



Partner purchases RYAH devices at wholesale cost



Partner sells RYAH devices at MSRP, and cartridges at a price set by partner



Partner is given a backend database to access all the consumption-habit statistics collected by partner's patients



The RYAH cartridges will only work with RYAH, creating a closed-loop recurring revenue stream for partner



RYAH Cartridges: From Seed to Consumption

What makes RYAH's QR cartridges Unique?

RYAH's cartridge based system allows for patients to monitor and record exactly how much they are consuming to ensure safe and effective use of dry herb.

- QR cartridges enable you to track your strains all the way from seed to consumption
- Disposable and proprietary cartridges create a closed-loop, recurring revenue ecosystem that ensures your patients will be frequent, repeat customers
- Pre-filled cartridges make life easy for those who don't want to grind and pack their herbs
- RYAH cartridges are discreet and childproof making it an ideal solution for older demographics
- RYAH's QR identifier allows for the integration of consumption data to feed into RYAHMD in order to manage a patient's medication regimen



Sales and Pricing Strategy

RYAH is uniquely positioned to capture both IoT and Data Intelligence Market for the \$100.3B Medical Plant Market



Hardware Pricing Strategy

Vaporizer Margin Wholesale : 129%
Vaporizer Margin Retail: 100%

Empty Cartridges Margin: 131%
Dispensary Filled Cartridges : Partners Set Their Price



Data Intelligence Strategy

- RYAH is seeking to become dominant data intelligence provider for doctors, hospitals, pharmacies and clinics
- AI and machine learning tools will create predictive analysis and monetized for Business Intelligence Market

RYAH Vaporizer Comparable

A highlight of several competitors' fundraising efforts:



Syqe Medical

- \$ 82 mm total investment
- Latest round of \$ 50mm closed December 31, 2018

The logo for Resolve, consisting of the word "RESOLVE" in a bold, uppercase, sans-serif font. The letter "O" is stylized with a horizontal line through its center.

RESOLVE

Resolve

- \$ 8,750,00 CAD at \$ 62 mm CAD valuation, plus \$ 10 mm CAD debt at 20 % pre-IPO
- December 2018 investment



STORZ & BICKEL

Storz & Bickel

- Acquired by Canopy Growth €145 million valuation
- December 2018 acquisition



PAX Labs

- \$ 547mm total investment
- Latest round of \$ 50.00 mm closed April 22, 2019



Milestones:

RYAH is now in commercial stage with 100k cartridges and 1,200 devices produced



Medical

- Health Canada Class I device filings: Q2 2019
- EU, Israel, Health and Health Canada Class II filings: Q4 2019
- FDA Filings: Q4 2019



Product

- US Market product rollout: Q3 2019
- Canada product rollout: Q4 2019
- EU / Israel : Q1 2020
- Australia: Q1 2020



R&D

- RYAH Vaporizer: Active
- RYAH Smart-patch: Q4, 2019
- RYAH oil and flower cartridge: Q1 2020
- RYAH Tincture Pen: Q2, 2020



Markets

- CSE Listing: Q3 2019
- OTC BB: Q2 2020
- Nasdaq Listing: Q2, 2020

MANAGEMENT TEAM

Boris Goldstein, PHD – Founder and Chairman

Dr. Boris Goldstein is a seasoned entrepreneur, venture capitalist and investment banker. Dr. Goldstein started his career in 1989 as founder of Software House HT, a startup technology company, which he developed into a worldwide corporation with over 40 offices in 17 countries. Since then Dr. Goldstein has founded and served on the board of directors and advisory boards of numerous companies in Silicon Valley and Silicon Alley, including Trans Global Ventures Group, Intelligent Video Systems, Visisys Holdings Plc., E-Trade Eurasia, Pacific Petroleum Technologies, E*Forex, Solby, CBSF Capital Management, CBSF International Fund, CBSF, Daldaris, Pacific Venture Fund, and FRB. During this period Dr. Goldstein was involved in dozens of financings totaling over \$700 million in consolidated debt/equity/ADR instruments. Dr. Goldstein brings experience in fundamental research, investment and technologies, and is the author of multiple patents and books.

Gregory Wagner, MBA – Chief Executive Officer

Greg is a 20+ year former financial markets global head and intrapreneur. He has held executive roles in both the United States as CEO of ABN AMRO's broker dealer, and in London as Head of Equity Prime Services for the Royal Bank of Scotland where Greg oversaw \$60b in assets under custody. Greg has co-founded and built several startups for the ground up. Greg holds FINRA Series 7, 63, 24, 55 licenses and an MBA in Finance from Fordham University. Greg has also received a Certification in Innovation and Strategy from Harvard University.

Mark Corrao- CFO

Mark has more than 45 years of experience in financial management with a proven track record of raising capital and has been instrumental in the initial registration of numerous public companies. Mark has developed, authored and presented numerous business plans and cash management and investment strategies.

ADVISORS

Dr. George Anastassov

Dr. Anastassov is the Chief Executive Officer, Chief Financial Officer and the Secretary of AXIM Biotechnologies, Inc. as of May 2014. With previous experience in both the cannabis industry, as well as the public markets, Dr. Anastassov provides unparalleled insight to Ryah Medtech IPO future.

Martin Tremblay

Martin Tremblay achieved tremendous success over his 10 years experience in the corporate and investment industry. Through his professional career, he has focused and accumulated strong experience by playing different roles in corporate development and strategies, capital market advisory and stock exchange listings only to name a few. For the past two years he has been working as a principal at Hamsa Capital Inc. and acting as an active investor in the portfolio of his clients. He successfully incorporates strategies that enable long time growth for these companies

Vincent Hope

Vincent Hogue is Vice-President of Brokerage and Private Banking at Desjardins Group and is responsible for all internal and external distribution networks for Desjardins wealth management investment products. In this capacity, he acts as Senior Vice President and Head of Personal Services for Desjardins Securities. He is responsible for managing all the activities of Desjardins Securities 'personal services division' and those of Desjardins' online brokerage division (Disnat). In addition, as Chairman of the Board of Directors of Desjardins Investment Management, Mr. Hogue is in charge of developing the business and strategies of the Desjardins Private Investment Management team.

Beth Dost


Elizabeth G. Dost is a registered nurse and senior healthcare executive, and is currently serving as a Senior Executive HealthCare Consultant in Emerging Industries, most noticeably in Medical Cannabis. Ms. Dost is a Certified Cannabis Nurse and Nominating Committee member of the American Cannabis Nurse Association, member of the Society for Cannabis Clinicians, Americans for Safe Access, Patients Out of Time, and the National Hospice and Palliative Care Organization (NHPCO) where she serves on their speaker's list.

Dr. Martha Montemayor


Martha is a cannabis industry professional since 2009 and has started Healthy Choices Unlimited medical cannabis evaluation clinic in 2012, which has seen over 20,000 patients since inception. Her experience rolling out one of the most successful clinics in one of the hottest cannabis markets provides PotBotics with important information on the western market.

RYAH 5 year Revenue Growth and Sales Projections

■ Ryah Revenue m



■ Capsules Sold ● Devices Sold



OUR INVESTMENT THESIS

Premium Innovation

First Artificial Intelligence (AI) system to fingerprint cannabinoid and map for medical conditions

Substantial Value

Comprehensive intellectual property portfolio

Brand Awareness

Highly recognized brand that has drawn significant media interest and holds high prestige in the medical CBD and herb market

Market Innovator

Created and commercialized RYAH, the world's first commercial grade dosing vaporizer

Recurring Revenue Model

Commercial stage, with multiple-prong strategy to generate revenue

Share Ownership	Millions
# of Shares Outstanding	69.75
Fully Diluted Shares	76
Insiders Ownership	21%
Market Cap – 2019, May 15 th ,	Investor rounds priced at \$.57 / share
Debt (to be converted with Financing)	nil

This presentation (the "Presentation") about Potobotics Inc. (the "Company") is dated as of July 2018. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.

Information in this Presentation

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. The information contained herein is considered current as of the date of this Presentation but will not be updated at any time thereafter, including as of the time of any closing (each, a "Closing") of any offering of securities of the Company (the "Securities"). All information contained herein is qualified by and subject to a Subscription Agreement (including all the representations and warranties of the parties thereto contained therein) to be effective as of the date of a Closing between the Company and a purchaser of Securities. This Presentation does not contain all of the information that would normally appear in a prospectus or offering memorandum under applicable Canadian securities laws. This Presentation contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate. By your acceptance of this presentation you and any person reviewing this Presentation agrees not to distribute, copy; reproduce; transmit; make available; or condone any of the foregoing, without the prior written consent of the Company. Any unauthorized use of this Presentation is strictly prohibited.

Forward-Looking Information

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

on your rights, you are encouraged to review this disclosure and are advised to consult independent legal counsel.

Cannabis Industry Disclaimer

The Company's business is connected to the cannabis industry including in the United States, which industry is illegal under United States federal law. The cultivation, sale and use of cannabis is illegal under United States federal law pursuant to the U.S. Controlled Substance Act of 1970 (the "CSA"). Under the CSA, the policies and regulations of the United States federal government and its agencies are that cannabis has no medical benefit and a range of activities including cultivation and the personal use of cannabis is prohibited. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and in case of conflict between federal and state law, the federal law shall apply. In addition, over half of the states of the United States have enacted legislation to legalize and regulate the sale and use of medical cannabis, while other states have legalized and regulate the sale and use of medical cannabis with strict limits on the levels of THC. There are a number of significant risks associated with entry into the cannabis industry. Unless and until the United States Congress amends the CSA with respect to medical and/or adult-use cannabis (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current federal law, which would deem any business involving producing, cultivating, extracting or dispensing cannabis in violation of federal law in the United States. The Company's activities or investments in the United States cannabis market will subject the Company to heightened scrutiny by regulators, stock exchanges, clearing agencies and other Canadian authorities. There are a number of risks associated with this.

Disclaimer

This Presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, or an advertisement or a public offering of the Securities in any province or territory of Canada, including Ontario, and does not constitute an offer for the sale of Securities. For a summary of all binding terms please see the subscription agreement (the "Subscription Agreement") to be used by the Company for the issuance of Securities. Securities have not been nor will they be qualified for sale to the public under applicable Canadian securities laws. Accordingly, Securities will be subject to restrictions on resale. No securities regulatory authority in Canada, the United States or any other jurisdiction has reviewed or in any way passed upon this Presentation or the merits of the Securities and any representation to the contrary is an offence. The Company is not, and it is not anticipated that it will become at any time, a reporting issuer or the equivalent thereof under the securities legislation of any jurisdiction. The Securities will not be listed on any stock exchange and there is no primary or secondary market for such Securities, nor is it anticipated that such market will develop. The Securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to U.S person. Any offer or sale of Securities will only be made on a private placement basis, under an exemption from the requirement that the Company prepare and file a prospectus with the relevant Canadian securities regulatory authorities. Offers and sales of Securities will be made through dealers that, in each case, is registered (or exempt from registration) under applicable securities laws. Securities will not be sold until a subscriber has executed and delivered a Subscription Agreement approved and accepted by the Company. The Company reserves the right to reject all or part of any offer to purchase Securities for any reason, or allocate to any prospective purchaser less than all of the Securities for which such purchaser has subscribed.

Statutory Rights of Action for Purchasers

This Presentation is not and is not intended by the Company to be an "offering memorandum" within the meaning of the applicable provincial securities legislation in which Securities may be distributed. If, notwithstanding the foregoing, a court or tribunal applying such legislation determines that this Presentation constitutes an "offering memorandum" within the meaning of such legislation, purchasers of Securities that have received this Presentation will be, upon acceptance by the Company of the purchase price for such Securities, granted certain statutory rights of action for damages or rescission if this Presentation contains a misrepresentation (as defined in applicable provincial securities legislation). For more information on your rights, you are encouraged to review this disclosure and are advised to consult independent legal counsel.